Short interfering RNAs (siRNAs) are as effective at targeting and silencing genes by RNA interference (RNAi) as long double-stranded RNAs (dsRNAs). siRNAs are widely used for assessing gene function in cultured mammalian cells or early developing vertebrate embryos. siRNAs are also promising reagents for developing gene-specific therapeutics. Specifically, the inhibition of HIV-1 replication is particularly well-suited to RNAi, as several stages of the viral life cycle and many viral and cellular genes can be targeted. The future success of this approach will depend on recent advances in siRNA-based silencing technologies.
Introduction
Eukaryotes have evolved a cellular defence system that responds to long double-stranded RNAs (dsRNAs) and protects their genomes against these invading foreign elements. dsRNA delivery into cells has been used to elucidate the role of cellular genes that are homologous in sequence to the introduced dsRNA, by means of sequence-specific gene silencing (Fire et al., 1998) . RNA interference (RNAi)-based reverse genetic analysis now provides a rapid link between sequence data and biological function. RNAi is particularly useful for analysing gene function in Caenorhabditis elegans (for reviews, see Hope, 2001; Kim, 2001) . Effective gene silencing typically requires long dsRNA (Parrish et al., 2000; Elbashir et al., 2001b) . Its application in vertebrate animals, including mammals, has proven to be more difficult because of the presence of additional dsRNA-triggered pathways that mediate non-specific suppression of gene expression (Caplen et al., 2000; Nakano et al., 2000; Oates et al., 2000; Zhao et al., 2001) . These non-specific responses to long dsRNA are not, however, triggered by short interfering RNAs (siRNAs) (Bitko & Barik, 2001; Caplen et al., 2001; Elbashir et al., 2001c; Zhou et al., 2002) . siRNAs can target genes as effectively as long dsRNAs (Elbashir et al., 2001b) and are widely used for assessing gene function in cultured mammalian cells or early developing vertebrate embryos (Harborth et al., 2001; Elbashir et al., 2002; Zhou et al., 2002) . siRNAs are also promising reagents for developing gene-specific therapeutics (Tuschl & Borkhardt, 2002) . This review focuses on RNAi as it relates to mammalian systems and on the application of siRNAs for targeting genes expressed in HIV-1-infected cell lines.
General mechanism of RNA interference
Since the demonstration that RNAi is activated by dsRNA, and the suggestion that RNAi might involve a dsRNA derivative (Fire et al., 1998) (Figure 1 ), plant and Drosophila studies have provided fundamental insights into the mechanism of RNAi. Long dsRNAs are first processed to siRNAs by the ribonuclease III (RNase III)-like enzyme Dicer (Cerutti et al., 2000; Hammond et al., 2000; Billy et al., 2001; Ketting et al., 2001) (Figure 1 ). In Drosophila melanogaster (D. melanogaster) embryo extracts and Dicer immunoprecipitates of D. melanogaster cells, the rate of siRNA formation is ATP-dependent; siRNAs produced in the embryo lysate are 1 nucleotide longer in the absence of ATP than in its absence (Zamore et al., 2000; . Compelling evidence from D. melanogaster extracts suggests that siRNA duplexes are assembled into a multicomponent nuclease, which guides the sequence-specific recognition of the target mRNA (Hammond et al., 2000; Yang et al., 2000; Zamore et al., 2000; Elbashir et al., 2001a) . This complex is referred to as the RNA-induced silencing complex (RISC) (Figure 1 ). RISC targets homologous sense, as well as antisense single-stranded RNAs (ssRNAs), for degradation in D. melanogaster embryo lysates (Elbashir et al., 2001a,b) . The cleavage sites for both sense and antisense target ssRNAs are located in the middle of the region spanned by the siRNA duplexes. The targets are cleaved precisely 10 nucleotide upstream of the target position that matches the most 5′ nucleotide of the sequence-complementary guide siRNA. Importantly the 5′, and not the 3′, end of the guide siRNA sets the ruler for target RNA cleavage (Elbashir et al., 2001a,b) .
Additionally, siRNA duplex function requires the presence of a 5′ phosphate at the target-complementary strand and ATP is used to maintain these 5′ phosphates (Nykanen et al., 2001) (Figure 1 ). Furthermore, in vitro transcribed synthetic siRNAs that carry 5′ triphosphates are active in human cell gene-silencing experiments (Donze & Picard, 2002; Paddison et al., 2002b) . In a recently developed in vitro HeLa cell system (Martinez et al., 2002a) , siRNA duplexes are also rapidly 5′ phosphorylated and siRNA targets RNA cleavage at exactly the same position as in D. melanogaster lysates. It has been difficult to detect potent and specific RNAi in commonly used mammalian cell-culture systems using long dsRNA, varying in length from 38-1662 bp (Caplen et al., 2000; Ui-Tei et al., 2000; Yang et al., 2001; Paddison et al., 2002a) . As RNAi exists in mouse oocytes and early embryos (Svoboda et al., 2000; Wianny & Zernicka-Goetz, 2000) , and RNAi-related transgenic-mediated co-suppression is observed in cultured Rat-1 fibroblasts (Bahramian & Zarbl, 1999) , the apparent lack of RNAi in mammalian cell culture was unexpected. However, it is known that dsRNA in the cytoplasm of mammalian cells can trigger profound physiological reactions that lead to the induction of interferon synthesis (Lengyel, 1987; Stark, et al., 1998; Barber, 2001) . In the interferon response, dsRNA longer than 30 bp binds and activates the protein kinase PKR and 2′,5′-oligoadenylate synthetase (2′,5′-AS) (Minks et al., 1979; Manche et al., 1992) . Activated PKR stalls translation by phosphorylating the translation-initiation factor eIF2α, whilst activated 2′,5′-AS causes mRNA degradation by stimulating RNase L. These responses are intrinsically sequence non-specific with respect to the inducing dsRNA.
More recently, Zeng & Cullen (2003) demonstrated that an endogenously encoded human miRNA is able to cleave an mRNA bearing fully complementary target sites, whereas an exogenously supplied siRNA can inhibit the expression of an mRNA bearing partially complementary sequences without inducing detectable RNA cleavage. These data suggest that miRNAs and siRNAs can use similar mechanisms to repress mRNA expression and that the choice of mechanism may be largely, or entirely, determined by how complementary they are to the RNA target.
Synthetic siRNAs
RNA interference, mediated by small interfering RNAs (siRNAs), is a powerful tool for dissecting gene function and drug target validation. siRNAs can be synthesized in large quantities and thus can be used to analyse a large number of sequences emerging from genome projects in a cost-effective manner. However, the phenomenon might reflect an incorrect sequence of RNAi, poor penetration of the mammalian cells by the nucleotides or insufficient knowledge of the protein in question. For delivery, siRNAs for gene-targeting experiments have only been introduced into cells via classic gene-transfer methods, such as liposome-mediated transfection, electroporation and microinjection, which require the chemical or enzymatic synthesis of siRNAs (Donze & Picard, 2002) . Synthetic siRNA duplexes can be incubated with lipid formulations to generate liposomes containing siRNA. In such formulations, The cellular RNase III enzyme Dicer processes double-stranded RNA (dsRNA) to 21-23 nt short interference RNA (siRNA) duplexes in an ATP-dependent manner. The siRNAs are incorporated into a siRNA-ribonucleoprotein complex (siRNP), which uses ATP to rearrange itself into the RNA-induced silencing complex (RISC) by unwinding the siRNA duplex. Once unwound, the single-stranded antisense siRNA guides RISC to mRNA with a complementary sequence, causing endonucleolytic cleavage of the target mRNA.
The mRNA cleavage products are then released. RISC might then be reactivated for another round of catalytic target RNA cleavage.
cationic lipids bind to oligoribonucleotides through anioncation and hydrophobic interactions. The efficiency of siRNA uptake is dependent upon cell type. Since high concentrations of cationic liposomes may be toxic to target cells, their application has to be optimized for each type of target cells (Felgner et al., 1994) . In particular, transfection efficiency into suspension cells, such as T-cell lines and primary cells using cationic liposomes, is often less than 10%. Most of the cationic lipid reagents in use today for siRNA are formulated as liposomes (Lipofectamine) containing two lipid species: the polycationic lipid, 2, 3-diolexyoloxy-N-[2(spermine carboxamido) ethyl] N,N-dimethyl-1propanammonium trifluoroacetate (DOSPA) and the neutral lipid, dioleoylphosphatidylethanolamine (DOPE) (3:1w/w). The efficient delivery of siRNA by Lipofectamine reagent has been reported for siRNAmediated RNA interference in cultured mammalian cells (Caplen et al., 2001; Elbashir et al., 2001c; Garrus et al., 2001; Paul et al., 2002) and siRNA-mediated anti-AIDS therapeutics (Gitlin et al., 2002; Jacque et al., 2002; Novina et al., 2002; Park et al., 2002 Park et al., , 2004 . Further development of liposomes in the future could enhance their utility for delivering siRNA to a broader range of target cells.
DNA vector-mediated short interfering RNAs or short hairpin RNAs siRNA-directed silencing by transfection is limited in mammals by its transient nature. To overcome some of the shortcomings of transfecting chemically synthesized siRNA into cells, several groups have developed DNA vector-mediated mechanisms to express substrates that can be converted into siRNA in vivo (Kennerdell & Carthew, 2000; Tavenarakis et al., 2000; Svoboda et al., 2001; Brummelkamp et al., 2002a; Lee et al., 2002; McManus et al., 2002; Miyagishi & Taira, 2002; Paddison et al., 2002a,b; Paul et al., 2002; Yu et al., 2002; Kawasaki & Taira, 2003) (Figure 2 ). Alternatively, small RNA molecules might also be expressed in the cell following the cloning of siRNA templates into RNA polymerase III (pol III) transcription units; these are based on the sequences of the natural transcription units of the small nuclear RNA U6 or the human RNase P RNA H1 (Medina & Joshi, 1999; Paule & White, 2000) . Two approaches have been used for the expression of siRNA species by constructs driven by RNA pol III. In the first approach, the sense and antisense strands of the siRNA duplex are expressed from different, usually tandem, promoters (Figure 2a ) Miyagishi & Taira, 2002; Yu et al., 2002) . These strands come together in vivo to form a 19 nucleotide duplex with 4 nucleotide overhangs from the pol III termination signal. The second approach uses Dicer to express and process short hairpin (sh)RNAs into siRNAs ( Figure 2b ). Dicer is required for processing pre-let7 RNA, a structured ~70 nucleotide hairpin, into the mature 22 nucleotide active species miRNA (Reinhart et al., 2000; Grishok et al., 2001; Hutvagner et al., 2001; Knight & Bass, 2001; Hutvagner & Zamore, 2002) . Brummelkamp and colleagues designed an H1 RNA pol III-based shRNA expression vector to produce hairpin RNA with a 19 nucleotide stem and a short loop (Brummelkamp et al., 2002a) (Figure 2c ). This system was used to inhibit the expression of CDH1 (E-cadherin) and p53 with an efficiency comparable to siRNA transfection. Using RNA structures based on the let7 precursor, Paddison et al. targeted Figure 2 . Endogenous expression of short interfering RNAs (a) Long hairpin RNA expressed from an RNA polymerase (pol II) promoter yields a population of siRNA with several sequence specificities. (b) Expression cassette for sense and antisense siRNAs using the tandem pol III snRNA promoter Miyagishi & Taira, 2002) . The target site preferably selected for optimal vector design is indicated at the bottom. (c) A single pol III cassette for expressing hairpin RNAs that are subsequently processed to siRNAs (Myslinski et al., 2001; Brummelkamp et al., 2002a; Paddison et al., 2002b; Paul et al., 2002; Sui et al., 2002; Yu et al., 2002) . In this case, transcript synthesis is initiated with a +1 guanosine, and the 3′ end of the sense strand is joined by short oligonucleotide loops with the antisense strand.
sequence in the hairpin's stem (Paddison et al., 2002b) . When transfected into Drosophila S2 cells, they found that, although the let7-based structures could target the luciferase mRNA, the most effective inhibitors had a simple hairpin structure that was fully complementary to the stem. To express hairpin RNA in mammalian cells, they developed a U6 RNA pol III-based expression system, which used a 29 nucleotide sequence complementary to the luciferase gene and an 8-nucleotide loop. Although most expression systems use either the U6 or H1 promoter, Kawasaki et al. recently described an expression system that uses the transfer (t)RNA Val promoter. shRNAs that have been generated from this expression system show a strong cytoplasmic localization and are efficiently processed by Dicer into siRNAs (Kawasaki & Taira, 2003) .
Some investigators have employed viral vectors in order to facilitate the introduction of siRNA-expressing cassettes into cells. Human immunodeficiency virus (HIV)-1-based lentivirus vectors have garnered particular attention in this regard. These vectors exploit the ability of HIV-1 to infect nondividing cells (Weinberg et al., 1991; Bukrinsky et al., 1992; Lewis et al., 2002) . HIV-1-based lentivirus vectors retain this central characteristic and, as such, are particularly suited for the transduction of non-dividing cells such as neurons and haematopoietic progenitor cells (Naldini et al., 1996) .
Lentivirus vectors expressing shRNAs have been shown to promote specific gene silencing in primary dendritic cells (Stewart et al., 2003) , whilst CD8-specific shRNAs expressed from an HIV-1-based vector have been found capable of silencing CD8 expression in vitro and in vivo (Rubinson et al., 2003) . Collectively, these studies illustrate the broad utility of RNAi for the silencing of viral and cellular processes in vitro and in vivo.
Inhibition of HIV-1 replication by RNA interference
The introduction of combination antiretroviral therapy has resulted in a remarkable improvement in the life expectancy of individuals infected with HIV and has reduced their likelihood of developing acquired immunodeficiency syndrome (AIDS). Despite this progress, HIV infection remains an incurable disease. Toxicity problems associated with current drug therapies and the emergence of drug resistance clearly suggest the need for alternative therapeutic approaches. Retroviral infection with HIV results in the stable integration of proviral DNA into the genome of target cells, and can therefore be thought of as an acquired genetic disease. Thus, the modulation of HIV replication by expression of antiviral genes might be a therapeutic option for HIV infection. Baltimore (1988) was the first to suggest the concept of gene therapy as an intracellular immunization against HIV. Recently, a large number of different anti-HIV gene therapy approaches have been developed and tested in clinical trials. The gene therapy strategies can be divided into two main categories: genetic modification of HIV target cells, or their progeny, in order to inhibit HIV replication and genetic modification of cells to generate an immune response against HIV or HIVinfected cells. The second category can be described as gene therapy-based immunotherapy and will not be discussed further in this review.
Inhibition of HIV replication involves the transfer of genetic material into HIV-1 target cells or their progenitor cells (CD4 + T cells or haematopoietic stem cells). A typical approach for HIV-1 gene therapy infection is schematically depicted in Figure 3 . HIV-1 is especially well suited to target RNAi because dsRNAs act at multiple steps of the HIV-1 replication cycle (Figure 3) . The inhibitory proteins used against HIV act intracellularly; they include antibody fragments, single-chain variable fragments, transdominant negative HIV and cellular proteins. Most of these approaches target viral RNA or proteins. Additional cellular factors that are prerequisites for HIV infection or replication are also potential targets for anti-HIV gene therapy. A number of studies have shown that transient transfection of siRNA directed to several HIV-1 genes (p24, HIV-1 LTR, vif nef, tat and rev) induced pre-integrated HIV-1 RNA degradation and consequently reduced HIV-1 antigen production by infected cells (Brummelkamp et al., 2002a; Capodici et al., 2002; Coburn & Cullen, 2002; Jacque et al., 2002; Lee et al., 2002; Lewis et al., 2002; Novina et al., 2002; Paul et al., 2002; Song et al., 2003; Surabhi & Gaynor, 2002; Yamamoto et al., 2002; Yu et al., 2002) . Further studies demonstrated that siRNA acted at a later stage of the HIV-1 life cycle causing post-integration degradation of HIV-1 RNA transcripts ( Jacque et al., 2002; Lee et al., 2002; Novina et al., 2002) .
The HIV-1 gag gene is expressed during the later steps of HIV-1 replication and encodes the gag-precursor protein, which is proteolytically cleaved to p24 and other polypeptides. p24 forms the HIV-1 core and functions by uncoating and packaging viral RNA. Novina et al. (2002) transfected cells with anti-gag siRNA, exposed them to HIV-1 and observed a decrease in the in vitro production of p24. Co-transfections by Jacque et al. (2002) of a proviral HIV-1 clone, 19-bp stem siRNAs, directed against other HIV-1 genes such as vif and TAR, and insertational mutagenesis of nef by a GFP gene, showed a significant suppression of virus production compared with non-transfected cells. Lee et al. (2002) used an alternative approach of targeting the HIV-1 rev gene with a mammalian pol III promoter system expressing targeted sense and antisense strands; they observed a marked reduction (<4 log 10 ) in expression of a rev-EGFP fusion protein.
Such siRNA or shRNA expression systems, if stable, could enable long-term target-gene suppression in cells (Naldini et al., 1996; Brummelkamp et al., 2002a; Paddison et al., 2002b; Paul et al., 2002; Lewis et al., 2002; Yu et al., 2002) . We have shown that dsRNA specifically suppresses the expression of HIV-1 genes (Park et al., 2002) . To study dsRNA-mediated gene interference in HIV-1 infected cells, six long dsRNAs were designed that targeted the HIV-1 gag and env genes. HIV-1 replication was totally suppressed in a sequence-specific manner by the dsRNAs in HIV-1 infected cells. In particular, the E2-dsRNA containing the major CD4 binding-domain sequence of gp 120 to target the HIV-1 env gene dramatically inhibited the expression of the HIV-1 p24 antigen in peripheral blood mononuclear cells (PBMCs) for 2 weeks.
More effective inhibition of HIV-1 replication was achieved by the use of four siRNAs targeted to several regions of the HIV-1 env genes (Park et al., 2003) . The mRNA targets for siRNAi were selected from the middle of the env regions in the HIV-1 genome, as we previously found that 531 bp (7070-7600) E2-dsRNAs, complementary to the env mRNA-containing V3 loop and the major CD4 binding-domain sequence of gp 120, were more effective inhibitors than those targeted to the gag gene. Furthermore, the envelope protein (Env) of HIV-1 mediates functions that are critical to the viral life cycle, including the viral attachment to target cells and the fusion of viral and cellular membranes.
In another study, Novina et al. (2002) showed that specific siRNAs directed against either CD4 or gag genes were able to prevent HIV-1 replication in MAGI and H9 cells. siRNA targeting rendered the receptor unavailable for virus attachment, so inhibiting HIV-1 entry and virus production. However, CD4 targeting might not be a feasible therapeutic approach because of its importance in immune function. By contrast, CCR5, which is the major HIV-1 co-receptor for viral entry into macrophages, might be a potentially useful cellular target; a 32-bp homozygous deletion of the gene abolishes its function without deleterious immunological consequences and provides protection from HIV-1 infection (Martinez et al., 2002b; Qin et al., 2003; Song et al., 2003) .
In this regard, RNAi offers a powerful tool with which to determine the role of cellular co-factors in HIV-1 replication. Indeed, the first study to use RNAi in HIV-1 research silenced the expression of TSG-101, which is a component of the class E vacuolar protein-sorting pathway, by means of siRNAs (Garrus et al., 2001) . This revealed a critical role for TSG-101 in the budding of HIV-1 virions. Moreover, Qin et al. have shown that a lentivirus vector, expressing potent siRNA against CCR5, can substantially reduce CCR5 expression on the cell surface in a specific manner and thereby render the transduced cells relatively resistant to CCR5-tropic HIV-1 infection (Qin et al., 2003) . Lee et al. (2003) also show inhibition of HIV-1 replication in macrophages by using tat or CCR5 directly from a a lentivirus vector. Similarly, siRNA directed against CXCR4 co-receptors blocked HIV-1 entry, and protected cells from infection and delayed virus replication (Anderson et al., 2003) .
Surprisingly, two recent studies indicate that siRNA can induce global upregulation of the expression of interferonstimulated genes (Sledz et al., 2003; Bridge et al., 2003) . This effect was detected with synthetic siRNA that were transfected into cells and with siRNA produced within cells by the expression of shRNA. Both papers document significant non-specific changes in gene expression as a consequence of the delivery of siRNAs. Sledz et al. (2003) observed a twofold induction of 52 out of 850 putative interferon-stimulated genes using synthetic siRNAs. On the other hand, Bridge et al. (2003) observed a 50-fold induction of the interferon stimulated gene OAS1 with only one siRNA vector and a 500-fold induction when two vectors were used simultaneously. These results suggest that the ability to induce the interferon system depends on some aspects of both the siRNA sequence and their method of delivery. Both groups point out that increasing the quantity of siRNA delivered enhances the effect. One simple precaution to limit the risk of inducing an interferon response is to use the lowest effective dose of shRNA vector as Bridge et al. advocate. Furthermore, the variability of HIV caused by its errorprone reverse transcriptase has been shown to generate mutations in the gene being targeted and thus rapidly evades siRNA (Boden et al., 2003) . Similar results have been observed with RNAi of a poliovirus infection (Gitlin et al., 2002) . Both papers indicate that the point mutation occurred in the middle to signal target sequences. Two recent studies have demonstrated that transfection with siRNA containing mismatches to the target sequence in the middle of the siRNA molecule reduces the efficiency of gene silencing (Brummelkamp et al., 2002b; Amarguioni et al., 2003) . These findings suggest that in order for RNAi to durably suppress HIV-1 replication, more potent shRNAs need to be designed that target highly conserved regions of the viral genome (for example, gag and pol) that are essential to the viral life cycle. Alternatively, there is a need for RNAi constructs co-expressing multiple shRNAs to be developed. These should simultaneously target different regions of the viral genome, thereby reducing the probability of generating shRNA escape mutants.
More recently, Banerjea et al. introduced anti-Rev siRNAs into CD34 + haematopoietic progenitor cells using lentiviral vectors . The cells underwent normal differentiation and the T cells in SCID-hu mouse thymus/liver grafts demonstrated a marked resistance to the HIV-1 virus.
Conclusions
The available treatments for patients with HIV-1 infection are associated with significant clinical improvements but also disadvantages such as cost, toxicity, induction of virus resistance and lack of patient compliance. Gene therapy strategies for HIV-1 infection have received increased attention because of the lack of chemotherapeutic drugs or vaccines that show long-term efficacy in vivo. Moreover, recent years have seen improvements at the basic science and clinical levels of gene therapy strategies and techniques. The new RNAi technology promises to impact greatly on HIV and AIDS research.
One question that arises from these studies is which stage in the HIV-1 life cycle siRNA inhibits replication. Therefore, approaches that target different stages of the viral life cycle, including viral entry and pre-and post-integration steps, are desirable. A single promoter can be used in the vector construct to drive a transcript with multiple siRNA motifs which can be processed in vivo.
Sustained inhibitory activity is an important factor in the design of HIV-1 therapeutic strategies. Stem-loop structures therefore offer a distinct advantage by conferring a higher degree of intracellular stability to siRNA. As well as rendering cells non-permissive for HIV-1 replication, lentivirus siRNA-expression vectors also have the potential to induce the stable knockout of important cellular genes unrelated to the HIV-1 life cycle in either cultured cells or experimental animals. Furthermore, the relative simplicity of the siRNA approach lends itself well to combinations with other Figure 3 . RNA interference target sites in HIV-1 replication cycle siRNA that targets HIV-1 RNA might induce the cleavage of pre-integrated RNA or interfere with post-integration HIV-1 RNA transcripts and block progeny virus production. siRNA targeting CD4, CXCR4 or CCR5 RNA transcripts inhibits virus attachment to the CD4 receptor or chemokine receptor-mediated HIV-1 fusion and entry. As cleavage of the mRNA target requires a high degree of complementarity between siRNA and its target sequence, heterogeneity in the virus population might prevent efficient silencing of some virus variants by specific siRNA. siRNAs directed to different regions of CCR5 or HIV-1specific genes, leading to additive or synergistic effects that might help prevent the escape of mutant variants. It seems possible that further modifications in vector design, and the selection of siRNAs simultaneously targeting multiple viral replication components, could provide an effective anti-HIV-1 treatment.
